Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

561 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR.
Hui CH, Goh KY, White D, Branford S, Grigg A, Seymour JF, Kwan YL, Walsh S, Hoyt R, Trickett A, Rudzki B, Ma DD, To LB, Hughes TP. Hui CH, et al. Among authors: seymour jf. Leukemia. 2003 May;17(5):821-8. doi: 10.1038/sj.leu.2402917. Leukemia. 2003. PMID: 12750692
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
Prince HM, Mileshkin L, Roberts A, Ganju V, Underhill C, Catalano J, Bell R, Seymour JF, Westerman D, Simmons PJ, Lillie K, Milner AD, Iulio JD, Zeldis JB, Ramsay R. Prince HM, et al. Among authors: seymour jf. Clin Cancer Res. 2005 Aug 1;11(15):5504-14. doi: 10.1158/1078-0432.CCR-05-0213. Clin Cancer Res. 2005. PMID: 16061867 Clinical Trial.
The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
Ritchie DS, Seymour JF, Grigg AP, Roberts AW, Hoyt R, Thompson S, Szer J, Prince HM. Ritchie DS, et al. Among authors: seymour jf. Ann Hematol. 2007 Feb;86(2):101-5. doi: 10.1007/s00277-006-0193-2. Epub 2006 Nov 7. Ann Hematol. 2007. PMID: 17089127 Clinical Trial.
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Harrison SJ, Quach H, Link E, Seymour JF, Ritchie DS, Ruell S, Dean J, Januszewicz H, Johnstone R, Neeson P, Dickinson M, Nichols J, Prince HM. Harrison SJ, et al. Among authors: seymour jf. Blood. 2011 Dec 8;118(24):6274-83. doi: 10.1182/blood-2011-03-339879. Epub 2011 Sep 12. Blood. 2011. PMID: 21911830 Free article. Clinical Trial.
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, Cui Y, Busman TA, McKeegan EM, Krivoshik AP, Enschede SH, Humerickhouse R. Roberts AW, et al. Among authors: seymour jf. J Clin Oncol. 2012 Feb 10;30(5):488-96. doi: 10.1200/JCO.2011.34.7898. Epub 2011 Dec 19. J Clin Oncol. 2012. PMID: 22184378 Free PMC article. Clinical Trial.
561 results